Exploring LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Treating Claudin 18.2-Positive Gastric or Gastroesophageal Junction Cancer with Peritoneal Spread

What this Trial Is About

Researchers are evaluating treatments for Claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma with peritoneal metastasis. This Phase 2 study aims to explore the effects of LM-302 and S-1 combined with intraperitoneal paclitaxel, with or without the addition of Cadonilimab. The study focuses on patients with advanced cancer that has spread to the lining of the abdomen and who meet specific diagnostic criteria. Participants will be randomly assigned to one of two treatment groups. The first group receives LM-302 intravenous infusion, intraperitoneal paclitaxel on days 1 and 8, and oral S-1 based on body surface area taken twice daily for 14 days every 3 weeks. The second group receives the same regimen with the addition of Cadonilimab intravenous infusion on day 1. Treatment cycles repeat every three weeks, with monitoring continuing for up to 36 months. Throughout the study, participants will undergo regular assessments including survival rates at one year, progression-free survival, overall survival, disease control, response rates, and pathological responses. Researchers will also monitor treatment-related side effects for up to 24 months. The total follow-up may last up to three years, with ongoing evaluations to assess safety and effectiveness of the treatments.

LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study